Analysis of drug transporter gene polymorphisms in an elderly patient with chronic myeloid leukemia successfully treated with intermittent low‐dose dasatinib

Transport and metabolism of tyrosine kinase inhibitors associated with chronic myeloid leukemia therapy: a review

(2022) Veerandra Kumar et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

Impact of genetic polymorphisms of drug transporters ABCB1 and ABCG2 and regulators of xenobiotic transport and metabolism PXR and CAR on clinical efficacy of dasatinib in chronic myeloid leukemia

(2022) Anna Marta Madejczyk et al.   Frontiers in Oncology

Genetic Polymorphisms and Adverse Events on Unbound Imatinib and Its Active Metabolite Concentration in Patients With Gastrointestinal Stromal Tumors

(2019) Yi Qian et al.   Frontiers in Pharmacology

Severe adverse events by tyrosine kinase inhibitors decrease survival rates in patients with newly diagnosed chronic-phase chronic myeloid leukemia

(2018) Shuichi Ota et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Plasma and intracellular concentrations in an elderly patient with chronic myeloid leukemia receiving low-dose dasatinib therapy

(2018) Masahiro Imamura et al.   Geriatrics & Gerontology International

Towards Comprehension of the ABCB1/P-Glycoprotein Role in Chronic Myeloid Leukemia

(2018) Raquel Maia et al.   MOLECULES

Genetic Polymorphisms Contribute to the Individual Variations of Imatinib Mesylate Plasma Levels and Adverse Reactions in Chinese GIST Patients

(2017) Jing Liu et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Influence of MDR1 and CYP3A5 genetic polymorphisms on trough levels and therapeutic response of imatinib in newly diagnosed patients with chronic myeloid leukemia

(2017) Natarajan Harivenkatesh et al.   PHARMACOLOGICAL RESEARCH

Efficacy of intermittently administered dasatinib with a reduced dose in an elderly patient with chronic myeloid leukemia

(2016) Masahiro Imamura   Geriatrics & Gerontology International

ABCB1 1199G>A polymorphism (rs2229109) affects the transport of imatinib, nilotinib and dasatinib

(2016) Géraldine Dessilly et al.   PHARMACOGENOMICS